Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Dinusha N. Udukala; Hongwang Wang; Sebastian O. Wendel; Aruni P. Malalasekera; Thilani N. Samarakoon; Asanka S. Yapa; Gayani Abayaweera; Matthew T. Basel; Pamela Maynez; Raquel Ortega; Yubisela Toledo; Leonie Bossmann; Colette Robinson; Katharine E. Janik; Olga B. Koper; Ping Li; Massoud Motamedi; Daniel A. Higgins; Gary Gadbury; Gaohong Zhu; Deryl L. Troyer; Stefan H. Bossmann

doi:10.3762/bjnano.7.33

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Dinusha N. Udukala, Hongwang Wang, Sebastian O. Wendel, Aruni P. Malalasekera, Thilani N. Samarakoon, Asanka S. Yapa, Gayani Abayaweera, Matthew T. Basel, Pamela Maynez, Raquel Ortega, Yubisela Toledo, Leonie Bossmann, Colette Robinson, Katharine E. Janik, Olga B. Koper, Ping Li, Massoud Motamedi, Daniel A. Higgins, Gary Gadbury, Gaohong ZhuDeryl L. Troyer, Stefan H. Bossmann

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Proteases, including matrix metalloproteinases (MMPs), tissue serine proteases, and cathepsins (CTS) exhibit numerous functions in tumor biology. Solid tumors are characterized by changes in protease expression levels by tumor and surrounding tissue. Therefore, monitoring protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. Water-dispersable Fe/Fe₃O₄-core/shell based nanoplatforms for protease detection are capable of detecting protease activity down to sub-femtomolar limits of detection. They feature one dye (tetrakis(carboxyphenyl)porphyrin (TCPP)) that is tethered to the central nanoparticle by means of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. Based on the protease activities of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, and 13, as well as CTS B and L, human breast cancer can be detected at stage I by means of a simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, demonstrates the feasibility of proteaseactivity- based liquid biopsies for early cancer diagnosis.

Original language	English (US)
Pages (from-to)	364-373
Number of pages	10
Journal	Beilstein Journal of Nanotechnology
Volume	7
Issue number	1
DOIs	https://doi.org/10.3762/bjnano.7.33
State	Published - 2016

Keywords

Biophotonics
Breast cancer
Iron/iron oxide nanoparticle
Liquid biopsy
Nanodiagnostics detection
Nanomedicine
Sub-femtomolar limit of detection

ASJC Scopus subject areas

General Materials Science
General Physics and Astronomy
Electrical and Electronic Engineering

Access to Document

10.3762/bjnano.7.33

Cite this

Udukala, D. N., Wang, H., Wendel, S. O., Malalasekera, A. P., Samarakoon, T. N., Yapa, A. S., Abayaweera, G., Basel, M. T., Maynez, P., Ortega, R., Toledo, Y., Bossmann, L., Robinson, C., Janik, K. E., Koper, O. B., Li, P., Motamedi, M., Higgins, D. A., Gadbury, G., ... Bossmann, S. H. (2016). Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection. Beilstein Journal of Nanotechnology, 7(1), 364-373. https://doi.org/10.3762/bjnano.7.33

Udukala, DN, Wang, H, Wendel, SO, Malalasekera, AP, Samarakoon, TN, Yapa, AS, Abayaweera, G, Basel, MT, Maynez, P, Ortega, R, Toledo, Y, Bossmann, L, Robinson, C, Janik, KE, Koper, OB, Li, P, Motamedi, M, Higgins, DA, Gadbury, G, Zhu, G, Troyer, DL & Bossmann, SH 2016, 'Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection', Beilstein Journal of Nanotechnology, vol. 7, no. 1, pp. 364-373. https://doi.org/10.3762/bjnano.7.33

@article{e3310c1b36b6449f903c80b00bcdbd3c,

title = "Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection",

abstract = "Proteases, including matrix metalloproteinases (MMPs), tissue serine proteases, and cathepsins (CTS) exhibit numerous functions in tumor biology. Solid tumors are characterized by changes in protease expression levels by tumor and surrounding tissue. Therefore, monitoring protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. Water-dispersable Fe/Fe3O4-core/shell based nanoplatforms for protease detection are capable of detecting protease activity down to sub-femtomolar limits of detection. They feature one dye (tetrakis(carboxyphenyl)porphyrin (TCPP)) that is tethered to the central nanoparticle by means of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. Based on the protease activities of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, and 13, as well as CTS B and L, human breast cancer can be detected at stage I by means of a simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, demonstrates the feasibility of proteaseactivity- based liquid biopsies for early cancer diagnosis.",

keywords = "Biophotonics, Breast cancer, Iron/iron oxide nanoparticle, Liquid biopsy, Nanodiagnostics detection, Nanomedicine, Sub-femtomolar limit of detection",

author = "Udukala, {Dinusha N.} and Hongwang Wang and Wendel, {Sebastian O.} and Malalasekera, {Aruni P.} and Samarakoon, {Thilani N.} and Yapa, {Asanka S.} and Gayani Abayaweera and Basel, {Matthew T.} and Pamela Maynez and Raquel Ortega and Yubisela Toledo and Leonie Bossmann and Colette Robinson and Janik, {Katharine E.} and Koper, {Olga B.} and Ping Li and Massoud Motamedi and Higgins, {Daniel A.} and Gary Gadbury and Gaohong Zhu and Troyer, {Deryl L.} and Bossmann, {Stefan H.}",

note = "Publisher Copyright: {\textcopyright} 2016 Udukala et al.",

year = "2016",

doi = "10.3762/bjnano.7.33",

language = "English (US)",

volume = "7",

pages = "364--373",

journal = "Beilstein Journal of Nanotechnology",

issn = "2190-4286",

publisher = "Beilstein-Institut Zur Forderung der Chemischen Wissenschaften",

number = "1",

}

TY - JOUR

T1 - Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

AU - Udukala, Dinusha N.

AU - Wang, Hongwang

AU - Wendel, Sebastian O.

AU - Malalasekera, Aruni P.

AU - Samarakoon, Thilani N.

AU - Yapa, Asanka S.

AU - Abayaweera, Gayani

AU - Basel, Matthew T.

AU - Maynez, Pamela

AU - Ortega, Raquel

AU - Toledo, Yubisela

AU - Bossmann, Leonie

AU - Robinson, Colette

AU - Janik, Katharine E.

AU - Koper, Olga B.

AU - Li, Ping

AU - Motamedi, Massoud

AU - Higgins, Daniel A.

AU - Gadbury, Gary

AU - Zhu, Gaohong

AU - Troyer, Deryl L.

AU - Bossmann, Stefan H.

PY - 2016

Y1 - 2016

N2 - Proteases, including matrix metalloproteinases (MMPs), tissue serine proteases, and cathepsins (CTS) exhibit numerous functions in tumor biology. Solid tumors are characterized by changes in protease expression levels by tumor and surrounding tissue. Therefore, monitoring protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. Water-dispersable Fe/Fe3O4-core/shell based nanoplatforms for protease detection are capable of detecting protease activity down to sub-femtomolar limits of detection. They feature one dye (tetrakis(carboxyphenyl)porphyrin (TCPP)) that is tethered to the central nanoparticle by means of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. Based on the protease activities of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, and 13, as well as CTS B and L, human breast cancer can be detected at stage I by means of a simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, demonstrates the feasibility of proteaseactivity- based liquid biopsies for early cancer diagnosis.

AB - Proteases, including matrix metalloproteinases (MMPs), tissue serine proteases, and cathepsins (CTS) exhibit numerous functions in tumor biology. Solid tumors are characterized by changes in protease expression levels by tumor and surrounding tissue. Therefore, monitoring protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. Water-dispersable Fe/Fe3O4-core/shell based nanoplatforms for protease detection are capable of detecting protease activity down to sub-femtomolar limits of detection. They feature one dye (tetrakis(carboxyphenyl)porphyrin (TCPP)) that is tethered to the central nanoparticle by means of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. Based on the protease activities of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, and 13, as well as CTS B and L, human breast cancer can be detected at stage I by means of a simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, demonstrates the feasibility of proteaseactivity- based liquid biopsies for early cancer diagnosis.

KW - Biophotonics

KW - Breast cancer

KW - Iron/iron oxide nanoparticle

KW - Liquid biopsy

KW - Nanodiagnostics detection

KW - Nanomedicine

KW - Sub-femtomolar limit of detection

UR - http://www.scopus.com/inward/record.url?scp=84994030761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994030761&partnerID=8YFLogxK

U2 - 10.3762/bjnano.7.33

DO - 10.3762/bjnano.7.33

M3 - Article

AN - SCOPUS:84994030761

SN - 2190-4286

VL - 7

SP - 364

EP - 373

JO - Beilstein Journal of Nanotechnology

JF - Beilstein Journal of Nanotechnology

IS - 1

ER -

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this